Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Harrow (HROW) with an Overweight rating and $76 price target The firm cites a path to strong growth and profitability, and believes Harrow is on a path to become the leading diversified U.S. ophthalmology company, the analyst tells investors in a research note. Cantor says Harrow has a “very good” setup for Q2, and guidance for 2025 is potentially conservative.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW: